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SUBMISSION ON THE ACIP INQUIRY INTO 
"PATENTING OF BUSINESS SYSTEMS" 
MATTHEW RIMMER 
 
The Australian Centre for Intellectual Property in Agriculture (ACIPA) is a research centre 
based at the law schools of the Australian National University in Canberra and Griffith 
University in Brisbane.  It commenced operations in September 2000 to undertake research in 
issues relating to intellectual property law, and apply that knowledge to the scientific 
community and industry and rural bodies. The Centre's ultimate purpose is to foster an active 
environment in which Australia better protects and capitalises the products of research and 
innovation.   It has particular expertise in patent law and biotechnology. 
 
ACIPA would like to make a submission in respect to the ACIP inquiry into "Patenting of 
Business Systems".  It will limit its comments to the issues raised by the inquiry in respect of 
intellectual property and biotechnology. ACIPA suggests that the inquiry needs to pay special 
attention to the impact of patenting business systems upon the emerging field of bioinformatics. 
It maintains that bioinformatics should be outside the scope of allowable patent claims.  This 
submission builds upon research undertaken by ACIPA into intellectual property and 
bioinformatics.1 
 
 
                                                            
1  Rimmer, M.  "Beyond Blue Gene:  Intellectual Property and Bioinformatics", IIC, 2002 (forthcoming). 
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Part 1 
Bioinformatics 
 
Bioinformatics is the art and science of using computer systems to store, manage and analyse 
biological information.  It brings together the diverse disciplines of mathematics, statistics, 
engineering, and computer science to map and model genes and proteins.   Bioinformatics 
played a critical role in mapping the human genome in both the large public and commercial 
projects.  Robert Cook-Deegan notes: 
 
Databases, computers, and mathematical algorithms proved as important as DNA sequencing, cloning, 
and other more obviously biological techniques.  As geneticists produced a deluge of data during the 
1990s and beyond, those who understood hardware and software would play an increasingly important 
role.2 
 
The public consortium relied upon cloning methods to map the location of genes, dividing the 
genome into small blocks.  The private efforts lead by Celera Genomics engaged in whole 
genome shotgun sequencing, fracturing the DNA of an organism into small fragments and then 
using powerful computer sequencing machines to identify the base pairs at the end of each 
                                                            
2  Cook-Deegan, R.  The Gene Wars:  Science, Politics, And The Human Genome.  New York and London:  
WW Norton and Company, 1994, p. 288. 
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fragments.  The sequencing, storage and retrieval of genetic information have generated new 
possibilities for understanding the function and structure of genes and proteins. 
 
Gene chip or microarray technology has also been vital to the analysis of genetic sequences. 
Taking its lead from computer technology, this technique has revolutionized genomic 
research.3 Kevin Davies comments upon this technology: 
 
These DNA chips have generated the biggest buzz in molecular biology circles since the advent of the 
polymerase chain reaction - the technique invented by Kary Mullis that amplifies minute traces of DNA 
- some fifteen years ago.4 
 
Microarrays are vast libraries of short DNA sequences attached to tiny glass or silicon supports 
and are being used to screen nucleic acid population. This revolution in miniaturization and 
high throughput screening is analogous to what has occurred in the computer industry over the 
past decades. Consequently, more data can be obtained more quickly than ever before.  
Affymetrix is the dominant player in the microarray or genechip technology. The patent 
position is complex and lawsuits that relate to the patent rights in this technology are already 
                                                            
3  Ekins, R. and Chu, F.  "Microarrays: Their Origins and Applications", Trends in Biotechnology 1999, 
Vol. 17, p. 217; Sinclair, B. "Everything’s Great When It Sits on a Chip?:  A Bright Future for DNA Arrays", The 
Scientist, May 24, 1999, at 18; Sutherland, G. “The Human Genome Project”, Australian Journal Of Forensic 
Sciences,  2000, Vol. 32, p. 19-24. 
4  Davies, K. The Sequence:  Inside The Race For The Human Genome.  London:  Weidenfeld and 
Nicolson, 2001, p 218-219. 
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in progress on both sides of the Atlantic.5 Other companies such as Motorola and Hewlett 
Packard have entered into the market for microarrays and gene chips. 
 
Bioinformatics also plays an essential role in drug development.  High throughput screening 
involves the use of fully automated robotic technologies to test compounds against a molecular 
gene target identified by genomic approaches.  Combinatorial chemistry is used to generate 
vast on-line libraries of entirely novel chemical entities.   Researchers predict that the time and 
cost it takes to develop drugs will be significantly reduced by biology-based approaches. It now 
takes about 12 years and $500 million to bring a drug to market. William Haseltine, the Chief 
Executive Officer of Human Genome Sciences, declared: 
 
We think we can reduce this by about six years.  By both increasing the success rates and shortening the 
trial period, we think we can dramatically improve cost efficiency in drug discovery.6 
 
The providers of bioinformatics services can aid and assist pharmaceutical companies who are 
engaged in drug discovery.  They can also conceivably move into the business of developing 
and selling drugs themselves. 
 
Part 2 
Bioinformatics Patents 
                                                            
5  Gilbert, P and Walter, C. “Patents and the Human Genome Project - New Claims for Old”, Trends in 
Biotechnology, Vol. 19 (2), 2001, p. 49. 
6  Philipkoski, K.  "Genome Map Heralds Cheap Drugs", Wired News, 13 September 2000.  
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Biotechnology firms have been applying for patents over databases of genetic information, and 
other proprietary informatics systems for storing and analysing genomic variation data. They 
have been seeking patents for computer software and computer hardware related to the life 
sciences. They have been applying for patents over novel business methods that utilise 
technologies for providing genomic services to the pharmaceutical and biotechnology industry. 
 
Patent attorneys and lawyers have hailed the decision in State Street Bank as opening the way 
forward for the patenting of bioinformatic inventions.7  Ernest Buff is perhaps representative 
in his enthusiasm:  "State Street and its progeny will likely change the way in which 
biotechnology and bioinformatics industries do business".8  However, as Stephen Lesavich 
comments, such patents were well available before the State Street Bank.9 Most bioinformatic 
inventions - such as those related to software methods, software systems, data structures, the 
Internet and other software features - were capable of receiving patent protection with software 
patents under US patent law long before the State Street Bank and AT & T cases were decided. 
 
Several studies have considered whether the advice of patent attorneys and lawyers has been 
acted on by biotechnology and information technology firms. 
 
                                                            
7  Sung, L. and Pelto, D.  "Bioinformatics May Get Boost From 'State Street':  Software That Can 
Manipulate Vast Libraries Of Genetic Data May Receive Patent Protection", The National Law Journal, Vol. 21 
(8), 19 October 1998. 
8  Buff, E. et al  "State Street Alters Landscape Of Biotechnology and Bioinformatics", New Jersey Law 
Journal, Vol. 157 (4), 26 July 1999. 
9  Lesavich, S.  "Bioinformatic Tools", The National Law Journal, 16 October 2000.  
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Silico Research 
A recent study conducted by London-based consulting firm Silico Research found that only 50 
software-related patents had been issued by the US Patent and Trade Mark Office between 
1996 and 2001 to companies operating in the pharmaceutical, biotechnology, and genomics 
research.10  The study covered 317 companies.  The firm searched for United States patents 
assigned under the international classification G06, which covers computers, databases, 
networks, and computing methods. The study excluded biological, pharmacological and 
chemical patents.  It did not take account of pending patents.  It also excluded patents issued to 
software companies like Microsoft, Oracle and IBM. 
 
The senior partner of Silico Research Emmett Power found unexpected results regarding the 
number of patents over bioinformatics products: 
 
We were genuinely surprised by the lack of technology and method patents issued to pharmaceutical and 
biotechnology companies.  We had expected large pharmaceutical companies to be registering significant 
numbers of technology and method patents as a matter of course. 
After all, they employ teams of computer scientists in original research roles and they are highly 
patent-focused as part of their business and value creation methodology.  Add the fact that senior 
executives throughout the industry are preaching the importance of the convergence of life and 
information technologies and we had expected to see 'convergence patents' staked out across the 
landscape. 
                                                            
10  Power, E.  "Pharmaceutical Companies Are 'Failing To Patent New Technologies', Silico Research, 
London, 2 May 2001. 
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However, it appears that large pharmaceutical companies' intellectual property efforts are still 
exclusively focused on compounds and genes as research and development end-points.  In the process, 
they are ignoring the value of any original methods and computer technology developed to get to those 
end-points.11 
 
The study concluded that the leading patent issuers in the sector were Incyte and Affymetrix 
with six patents each.  They were followed by PE corporation with five patents, and Tripos, 3-
Dimensional Pharmaceuticals, and Entelos each had three patents.  A number of companies 
had registered one patent. 
 
Nature Biotechnology Study 
Another study published by Nature Biotechnology provides a sharper image of the changing 
marketplace of bioinformatics.12  Paolo Saviotti and his collaborators sought to assess the 
commercial activity in bioinformatics by searching the Derwent Biotechnology Abstracts 
(DBA) for patents containing the words "computer, computing, DNA chip, biochip, gene chip, 
bioinformatics or informatics". 
 
Saviotti and his collaborators found that the number of bioinformatics related patents has been 
increasing steadily from 1979 to 1997 after which there was a notable boom in patent 
applications, with a peak of sixty patents in 1998. 
 
                                                            
11  Ibid.  
12  Saviotti, P., de Looze M-A, Michelland, S., and Catherine, D.  "The Changing Marketplace Of 
Bioinformatics", Nature Biotechnology, 2000, Vol. 18 (12), p 1247. 
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The first group of patentees were companies and institutions interested in applying information 
technology to production processes.  The patents filed were much older (1983-1992).  The 
applicants were commonly Japanese or Russian. 
 
The second group of patentees were pharmaceutical companies, bioinformatics startups and 
public research institutes interested in applying information technology to research and 
development processes.  Examples include Affymetrix, Affymax and Human Genome 
Sciences.  The date of patents issued to these companies range between 1994 and 2000.   
 
The third group of patentees were companies and instrumentation firms interested in creating 
tools and solutions for research and development processes.  The companies include firms such 
as Motorola and Kodak which have been involved in mainstream electronics, IT and 
telecommunications.  The patents issued to these companies range from 1992 to 2000. 
 
United States Patent and Trade Mark Office 
Such developments will have implications for patent applications and patent examination.  The 
United States Patent and Trade Mark Office reports that the actual number of pending 
bioinformatics patents is relatively small.13  Anticipating a rush of patent applications in this 
emerging area, the organisation had the foresight set up a dedicated bioinformatics art unit in 
December 1999, which operates under the biotechnology centre.  Jasemine Chambers, the 
director of biotechnology at the United States Patent and Trade Mark Office remarked:  "We 
were a little surprised that we haven't seen the flood of applications that some people have 
                                                            
13  Toner, B.  "Bioinformatics Patents Remain A Rarity In IP-Heavy Biopharmaceutical Industry", 
Genomeweb.com, 4 July 2001. 
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predicted".14  Currently the 11 examiners in the bioinformatics art unit are processing a total of 
around 200 patents.  Of those, 160 are in various stages of prosecution and 40 are waiting to 
be examined.  Only 11 have issued from the unit so far.  With a turnaround goal of 36 months, 
Chambers expects a few more bioinformatics patents to issue over the next year. 
 
Future Trends 
Recently, a number of mainstream information technology companies - such as IBM, 
Microsoft, and Compaq - have invested in bioinformatics. Commentators wonder what effect 
the entrance of these new players might have on the market for bioinformatics: 
 
The movement of these IT-based entrants into the market is important because they are very large and 
powerful firms capable of shaking up the industrial structure of bioinformatics.  It is tempting to speculate 
that the expertise of these companies in other industries might be rapidly translated to software solutions 
that provide the kind of standardization, integration, and analysis of the data so sorely needed.15 
 
Furthermore, the information technology firms will have an important impact upon the field of 
bioinformatics.  Such companies have shown great talent in fully exploiting both copyright law 
and patent law in managing the protection of computer software and hardware.16  They may be 
able to translate such tactics and strategies in the management of intellectual property to the 
field of bioinformatics. The entry of information technology companies into the marketplace 
may result in a greater activity in patenting.  Thus the precedents in relation to Internet business 
                                                            
14  Ibid. 
15  Saviotti, P., de Looze M-A, Michelland, S., and Catherine, D.  "The Changing Marketplace Of 
Bioinformatics", Nature Biotechnology, 2000, Vol. 18 (12), p 1247.  
16  Likhovski, M., Spence, M. and Molineaux, M.  "The First Mover Monopoly:  A Study On Patenting 
Business Methods in Europe", Oxford Electronic Journal Of Intellectual Property Rights, November 2000.  
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methods patents have greater relevance to biotechnological inventions than has been previously 
been thought. They will have an important bearing upon whether bioinformatics - such as 
databases, computer software, and websites - can be patented. 
 
Part 3 
Policy Options 
 
Patentable Subject Matter 
First of all, ACIPA argues that special consideration should be given to the situation of 
bioinformatics.  Rebecca Eisenberg makes a strong case that bioinformatics might not be an 
appropriate subject matter for a patent claim. 
 
I believe that patent claims to DNA sequences stored in computer-readable medium represent a 
fundamental departure from the traditional patent bargain of exclusionary rights to tangible inventions in 
exchange for free disclosure of information and should not be allowed. And I begin from the premise 
that computer-readable medium is the only practical way to perceive and analyze large volumes of DNA 
sequence information, even something as relatively simple as the genome of haemophilus 
influenza…The claim to the sequence in computer-readable medium, in effect, gives the patent holder 
the right to restrict the ability of others to use the information in a computer-readable medium and thus 
precludes others from perceiving and analyzing the sequence information itself.17 
 
                                                            
17  Eisenberg, R.  "Molecules v Information:  Should Patents Protect Both?", Boston University Journal of 
Science and Technology Law, 2002, Vol. 8, p. 190. 
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Eisenberg stresses the differences between DNA sequence information and Internet business 
methods: “Of course DNA sequence information stored is not the same thing as a computer-
implemented business method, and it is certainly possible to define boundaries for the patent 
system that include the latter but not the former”.18  Two possible options are available in light 
of this conclusion - one radical; the other a reform.  The first radical solution is that 
bioinformatics should be excluded from a manner of manufacture.  The second response is to 
ensure that the standards of novelty and an inventive step are applied strictly in this field. 
 
Experimental Use and Fair Dealing 
Second, Rebecca Eisenberg comments that patent law is an inappropriate regime for the 
protection of data: 
 
Patents are the wrong form for that protection to take. They are a very dangerous form of intellectual 
property rights for information because there are so few safety valves built in to the patent system that 
constrain the rights of patent holders relative to other models that are out there. For example, unlike 
copyright law, patent law has no fair use defense. Maureen O'Rourke is here somewhere and has 
suggested that maybe it should but does not. Patent law has no real research exemption. Patent law has 
no defense for reverse engineering or for independent creation. Dennis Karjala was saying earlier that 
none of the proposals for database protection would preclude independent creation. Well, the patent 
would preclude independent creation of the same information.19 
                                                            
18  Eisenberg, R. “Re-examining the Role of Patents in Appropriating the Value of DNA Sequences”, Emory 
Law Journal, 2000, Vol. 49, p. 793. 
19  Eisenberg, R.  "Molecules v Information:  Should Patents Protect Both?", Boston University Journal of 
Science and Technology Law, 2002, Vol. 8, p. 190. 
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In the United States, Michigan Democrat Congresswoman, Lynn Rivers, has introduced 
legislation into the House of Representatives of the Congress aimed at preserving research 
innovation in genetics.20  Her proposal picks up on academic plans for reform.  Donna Gitter 
argues: "Congress also should codify an experimental-use exemption for public-sector 
researchers at the federal level and non-profit researchers".21 Similarly, Maureen O'Rourke 
argues that patent law needs a defence in respect of research and experimental use, along the 
lines of the defence of fair use in copyright law.22  The Australian Government should seriously 
consider implementing similar reforms to those proposed by Democrats Congresswoman Lynn 
Rivers.  Arguably, the scope of the experimental use exception should be broadly defined to 
encourage experimental testing and follow-on innovation.  Such an exception would dispel the 
threat of litigation to researchers working in the field of bioinformatics.   
 
Compulsory Licensing 
                                                            
20  The Genomic Research And Diagnostic Accessibility Act 2002 (US) HR 3697 and The Genomic Science 
And Technology Innovation Act 2002 (US) HR 3966. 
21  D. Gitter, "International Conflicts Over Patenting Human DNA Sequences In The United States And The 
European Union:  An Argument For Compulsory Licensing And A Fair Use Exemption" (2001) 76 New York 
University Law Review, 1623.  See also R. Eisenberg,  "Patents And The Progress Of Science" (1989) 56 
University Of Chicago Law Review, 1017; D. Gilat, Experimental Use And Patents (1995); and E. Barash, 
"Experimental Uses, Patents And Scientific Progress" (1997) 91 North-Western University Law Review, 667. 
22  M. O'Rourke, "Toward a Doctrine of Fair Use In Patent Law” (2000) 100(5) Columbia Law Review, 
1177. 
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Third, there are concerns that monopolistic actors will take charge as the bioinformatic 
community struggles towards an acceptable degree of standardisation on hardware and 
software.23  Brown and others comment: 
 
Small software developers, once characteristic of the bioinformatics sector, now tend to sell their 
products to much larger companies.  The fear is that the area may become increasingly dominated by a 
small number of commercial actors providing highly integrated visualisation, search and design 
packages.  Indeed, the dominance of the administrative sector by Microsoft is seen as one paradigm for 
the way in which computerised biological research will be increasingly served by monopolistic 
suppliers.24 
 
Compulsory licensing could also be applied in the context of Australia.25   There are admittedly 
problems in the judicial application of compulsory licensing, and the proper calculation of a 
reasonable royalty rate.  It has been said that such provisions are "cumbersome and expensive 
to apply".26  The Intellectual Property Competition Review advocated the reform of the 
compulsory licensing provisions.  It recommended that s. 135 of the Patents Act 1990 (Cth) be 
repealed and that s. 133(2) be amended to include an order requiring a compulsory license to 
                                                            
23  Brown, N., Nelis, A., Rappert, B. and Webster, A.  “Bioinformatics: A Technology Assessment Of 
Recent Developments In Bioinformatics And Related Areas Of research And Development Including High-
throughput Screening and Combinational Chemistry”, Final Report for the Science and Technological Options 
Assessment Unit, European Parliament, 1999, p 24-25.  
24  Ibid, p 25. 
25  Lawson, C.  "Patenting Genes And Gene Sequences", Federal Law Review, 2002, Vol. 30, p. 97. 
26  Justice Finkelstein in Bristol-Myers Squibb v FF Faulding Co & Ltd (2000) 46 IPR 553. 
14 
be subject to a competition test.27   The Federal Government responded cautiously that the 
existing tests should be retained and a competition test be added as an additional ground on 
which a compulsory licence can be obtained.  However sweeping reforms are needed to ensure 
that compulsory licensing can be deployed in the field of biotechnology. 
 
Patent Administration 
The developments in relation to business methods have been a spur for a reform of patent 
administration.  Most notably, Merges was prompted to consider a number of initiatives to 
improve the operation of the patent office.28  However, bioinformatics has quite unique and 
important implications in respect of patent administration, and the examination of prior art.  
Vondran and Florence comment: 
 
Bioinformatics inventions are unique, however, because they combine the use of a computer and/or 
software with biological information. It is crucial, therefore, for patent practitioners to fully understand 
the case law relating to computers and software as well as biotechnology. Certain aspects of the statutory 
requirements for patentability are also affected by blending these disciplines. Determining the identity of 
the person of ordinary skill in the art can be particularly difficult due to the multidisciplinary nature of 
the field and its rapid rate of change. As bioinformatics evolves, patent practitioners must be willing to 
                                                            
27  Intellectual Property Competition Review Committee, Review Of Intellectual Property Legislation 
Under The Competition Principles Agreement (Canberra:  Attorney-General's Department, 2000) 
28  Merges, R.  “As Many As Six Impossible Patents Before Breakfast: Property Rights For Business 
Concepts And Patent System Reform”, Berkeley Technology Law Journal Spring, 1999, Vol. 14 (2), p 577, 
http://www.law.berkeley.edu/institutes/bclt/pubs/merges/ 
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adapt if they want to meet the needs of a bioinformatics client. Such willingness must include stretching 
beyond one's initial training or background to be effective.29 
 
Therefore there will be a need for IP Australia to develop a cadre of examiners who can deal 
with the combination of information technology and biotechnology.  Consideration should be 
given to the development of a special unit to deal with bioinformatics along the lines of the 
United States Patent and Trade Mark Office.  Alternatively, there should be greater 
collaboration between examiners from the sections dealing with information technology and 
biotechnology. 
  
Conclusion 
 
ACIPA suggests that the ACIP inquiry into the patenting of business systems should take into 
special consideration the field of bioinformatics.  This cross-over between information 
technology and biotechnology is important to a number of emerging areas of research - 
including genomics, proteomics, pharmacogenomics, and biodiscovery.  ACIPA points out that 
the developments in relation to the patenting of computing programs and business methods 
have important implications for bioinformatics.  It identifies a number of studies, which suggest 
that there is a slow but steady take up of patents in relation to this emerging field.  ACIPA 
queries whether bioinformatics should be treated like other subject matter under patent law.  At 
best, the field should be excluded from the definition of manner of manufacture; at the very 
                                                            
29  Vondran, C. and Florence, R.  "Bioinformatics:  Patenting The Bridge Between Information Technology 
And The Life Sciences", The Journal Of Law And Technology, 2002, Vol. 42, p. 93. 
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least, there is a need for a strict application of novelty and inventive step.  There is a need for 
more expansive defences under patent law - such as experimental use and compulsory 
licensing.  Furthermore there is a need for the patent administration to be properly prepared in 
the examination in the field of bioinformatics. 
 
